echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Food News > Food Articles > Jin Xinnong Securities Affairs Representative Zou Jing resigns

    Jin Xinnong Securities Affairs Representative Zou Jing resigns

    • Last Update: 2021-10-09
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On the evening of September 30, Jin Xinnong issued an announcement stating that Zou Jing applied to resign from the post of securities affairs representative due to personal reasons.
    After resignation, she will no longer hold any position in Jin Xinnong.
    The resignation report will be effective from the date of delivery to the board of directors
    .

    Up to now, Zou Jing holds 65,000 shares of Jinxinnong, accounting for 0.
    0094% of Jinxinnong's total share capital, all of which are equity incentive shares, of which 26,000 shares have been lifted from sales restrictions
    .


    According to the "Shenzhen Jinxinnong Technology Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.